top health care

Houston hospitals soar on annual list ranking best in Texas

These Houston hospitals are the best in Texas and beyond. Photo via tmc.edu

Houston Methodist Hospital now shares its status as the state’s best hospital with Dallas’ UT Southwestern Medical Center.

In U.S. News & World Report’s latest ranking of Texas hospitals, Houston Methodist and UT Southwestern share the No. 1 spot. Last year, Houston Methodist was the lone holder of first-place honors in Texas.

The Houston Methodist system comprises a primary care facility within the Texas Medical Center and six community hospitals across the region. In all, Houston Methodist operates more than 2,600 patient beds and employs more than 29,700 people.

Overall, Houston hospitals fared well in this year’s Texas rankings:

  • Houston Methodist, No. 1
  • Baylor St. Luke’s Medical Center, No. 3
  • Memorial Hermann Hospital-Texas Medical Center, No. 4
  • Memorial Hermann Greater Heights Hospital, No. 6
  • Houston Medical Sugar Land Hospital, No. 9
  • Memorial Hermann Memorial Medical Center, No. 10

Specialty institutions in Houston also garnered accolades.

For instance, the University of Texas MD Anderson Cancer Center ranked first in the country for cancer care. Since the inception of the U.S. News & World Report survey in 1990, MD Anderson has been among the country’s top two institutions for cancer care.

“At MD Anderson, we remain singularly focused on eliminating cancer,” Dr. Peter WT Pisters, president of MD Anderson, says in a news release. “We are pleased to see this commitment recognized, but there is work still to be done.”

For its part, Houston Methodist nabbed national rankings in 10 specialties, including No. 4 for diabetes and endocrinology and No. 5 for gastroenterology and GI surgery.

Elsewhere in the Houston area:

  • Texas Children’s Hospital nailed down the No. 1 ranking among children’s hospitals in the state.
  • TIRR Memorial Hermann was again ranked as the Best Rehabilitation Hospital in Texas.
  • The Texas Heart Institute at Baylor St. Luke’s Medical Center claimed the No. 2 ranking among cardiovascular, heart, and vascular surgery facilities in the state.
  • The Menninger Clinic again makes the top 10 psychiatric hospitals. It ranked No. 7 in that specialty.

“A recent survey of U.S. News users revealed more than four in five (84 percent) consider a hospital’s quality metrics to be important factors when deciding where to seek treatment for a serious medical issue,” Ben Harder, chief of health analysis and managing editor at U.S. News, says in a news release. “Consumers want useful resources to help them assess which hospital can best meet their specific care needs.”

Harder adds that his publication’s hospital rankings “offer patients and the physicians with whom they consult a data-driven source for comparing performance in outcomes, patient satisfaction, and other metrics that matter to them.”

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted